BAY-356
BAY-356, a potent TWEAK receptor agonist, is an aglycosylated anti-TWEAK receptor antibody. BAY-356 triggers TWEAKR hyperactivation, activates NFκB and STAT1 pathways, and undergoes TWEAKR-dependent internalization. BAY-356 can be used for the research of colorectal cancer, bladder cancer, non-small cell lung cancer and pancreatic cancer[1][2].
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
|
TWEAK |
NF-κB |
STAT1 |
BAY-356 induces dose-dependent agonistic effects in TWEAK receptor-positive tumor cells, activating NFκB and STAT1 pathways, increasing TWEAKR expression and IL-8 secretion, activating caspase 3/7, and inhibiting proliferation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BAY-356 (1-40 mg/kg; i.v.; weekly; 4 weeks) at 10 mg/kg results in well-tolerated exposure in healthy Cynomolgus monkeys, with higher doses (20 and 40 mg/kg) causing slight to moderate organ toxicity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (healthy)[2]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.v.; once a week; 4 weeks
-
Result:Associated well-tolerated exposure with 10 mg/kg weekly dose (not exceeding toxic thresholds).
Caused slight to moderate toxicity in liver, kidneys, and pancreas with 10, 20, and 40 mg/kg weekly doses.
TNFRSF12A/TWEAKR/CD266
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)